Tags

Type your tag names separated by a space and hit enter

Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease.

Abstract

BACKGROUND

Few data exist related to the impact of roflumilast on health care utilization. This retrospective study estimated 30-day hospital readmission rates between patients who did and did not use roflumilast among those with COPD hospitalizations.

METHODS

Data were from MarketScan, a large US commercial health insurance claims database. Patients aged ≥40 years with at least one hospitalization for COPD between 2010 and 2011 were included. The roflumilast group included patients who used roflumilast within 14 days after the first hospitalization (index), while the comparison group (non-roflumilast) included patients who did not use roflumilast during the study period. Continuous enrollment for at least 6 months before and 30 days after the index date was required. The 30-day hospitalization rate was calculated after the index hospitalization. Conditional logistic regression with propensity score 1:3 matching was employed to assess the difference in 30-day hospital readmission rates between the roflumilast and non-roflumilast groups, adjusting for baseline characteristics, comorbidity, health care utilization, and COPD medication use within 14 days after the index date.

RESULTS

A total of 15,755 COPD patients met the selection criteria, ie, 366 (2.3%) in the roflumilast group and 15,389 (97.7%) in the non-roflumilast group. The mean (± standard deviation) age was 71±12.5 years and 52% were female. After propensity score matching, all-cause 30-day hospitalization rates were 6.9% and 11.1% in the roflumilast and non-roflumilast groups, respectively. COPD-related 30-day hospitalization rates were 6.3% and 9.2% in the roflumilast and non-roflumilast groups, respectively. Conditional logistic regression identified a significantly lower likelihood of all-cause 30-day readmission (odds ratio 0.59, 95% confidence interval 0.37-0.93, P=0.023) for roflumilast patients relative to non-roflumilast patients.

CONCLUSION

This study showed, in a real-world setting, that use of roflumilast was associated with a lower rate of hospital readmission within 30 days among patients hospitalized for COPD.

Authors+Show Affiliations

Georgetown University Medical Center, Washington, DC, USA.Health Economics and Outcomes Research, Forest Laboratories, LLC, an affiliate of Actavis, Inc., Jersey City, NJ, USA.Health Economics and Outcomes Research, Forest Laboratories, LLC, an affiliate of Actavis, Inc., Jersey City, NJ, USA.Department of Medicine, University of California, Irvine, CA, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25999706

Citation

Fu, Alex Z., et al. "Lower 30-day Readmission Rates With Roflumilast Treatment Among Patients Hospitalized for Chronic Obstructive Pulmonary Disease." International Journal of Chronic Obstructive Pulmonary Disease, vol. 10, 2015, pp. 909-15.
Fu AZ, Sun SX, Huang X, et al. Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:909-15.
Fu, A. Z., Sun, S. X., Huang, X., & Amin, A. N. (2015). Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease, 10, 909-15. https://doi.org/10.2147/COPD.S83082
Fu AZ, et al. Lower 30-day Readmission Rates With Roflumilast Treatment Among Patients Hospitalized for Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2015;10:909-15. PubMed PMID: 25999706.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease. AU - Fu,Alex Z, AU - Sun,Shawn X, AU - Huang,Xingyue, AU - Amin,Alpesh N, Y1 - 2015/05/12/ PY - 2015/5/23/entrez PY - 2015/5/23/pubmed PY - 2016/2/5/medline KW - chronic obstructive pulmonary disease KW - health care utilization KW - hospital readmission KW - roflumilast SP - 909 EP - 15 JF - International journal of chronic obstructive pulmonary disease JO - Int J Chron Obstruct Pulmon Dis VL - 10 N2 - BACKGROUND: Few data exist related to the impact of roflumilast on health care utilization. This retrospective study estimated 30-day hospital readmission rates between patients who did and did not use roflumilast among those with COPD hospitalizations. METHODS: Data were from MarketScan, a large US commercial health insurance claims database. Patients aged ≥40 years with at least one hospitalization for COPD between 2010 and 2011 were included. The roflumilast group included patients who used roflumilast within 14 days after the first hospitalization (index), while the comparison group (non-roflumilast) included patients who did not use roflumilast during the study period. Continuous enrollment for at least 6 months before and 30 days after the index date was required. The 30-day hospitalization rate was calculated after the index hospitalization. Conditional logistic regression with propensity score 1:3 matching was employed to assess the difference in 30-day hospital readmission rates between the roflumilast and non-roflumilast groups, adjusting for baseline characteristics, comorbidity, health care utilization, and COPD medication use within 14 days after the index date. RESULTS: A total of 15,755 COPD patients met the selection criteria, ie, 366 (2.3%) in the roflumilast group and 15,389 (97.7%) in the non-roflumilast group. The mean (± standard deviation) age was 71±12.5 years and 52% were female. After propensity score matching, all-cause 30-day hospitalization rates were 6.9% and 11.1% in the roflumilast and non-roflumilast groups, respectively. COPD-related 30-day hospitalization rates were 6.3% and 9.2% in the roflumilast and non-roflumilast groups, respectively. Conditional logistic regression identified a significantly lower likelihood of all-cause 30-day readmission (odds ratio 0.59, 95% confidence interval 0.37-0.93, P=0.023) for roflumilast patients relative to non-roflumilast patients. CONCLUSION: This study showed, in a real-world setting, that use of roflumilast was associated with a lower rate of hospital readmission within 30 days among patients hospitalized for COPD. SN - 1178-2005 UR - https://www.unboundmedicine.com/medline/citation/25999706/Lower_30_day_readmission_rates_with_roflumilast_treatment_among_patients_hospitalized_for_chronic_obstructive_pulmonary_disease_ L2 - https://dx.doi.org/10.2147/COPD.S83082 DB - PRIME DP - Unbound Medicine ER -